معرفی
Dr. William Anderson is a researcher affiliated with the School of Medicine's Department of Respiratory Medicine. His work focuses on advancing clinical understanding of COPD, asthma, and pharmacotherapeutic interventions. Key areas include beta-blocker efficacy in COPD patients, inhaled corticosteroid dosing strategies, small airway dysfunction, and biomarker-driven lung cancer screening. His research integrates clinical trials, pharmacogenomics, and advanced diagnostic techniques like impulse oscillometry. Recent studies investigate left ventricular hypertrophy's impact on COPD prognosis and genotype-guided asthma management. Dr. Anderson has contributed to over 30 peer-reviewed publications since 2009, emphasizing translational research between preclinical models and clinical practice.
Education details are not explicitly stated in the provided text. His research portfolio includes randomized controlled trials evaluating drug efficacy (e.g., bisoprolol vs celiprolol in COPD, autoantibody-based lung cancer screening), pharmacokinetic studies of inhaled medications, and explorations of β2-adrenergic receptor polymorphisms' effects on asthma control. Collaborative studies with cardiovascular specialists address cardiopulmonary comorbidities in COPD patients. Current efforts focus on improving COPD management through better understanding of dynamic hyperinflation mechanisms and domiciliary safety protocols.
No scientific awards are listed in the provided information. His work involves multidisciplinary teams addressing unmet needs in small airways disease and corticosteroid optimization. Ongoing projects include refining inhaled corticosteroid particle size formulations and evaluating real-world outcomes of long-acting bronchodilator use in COPD.
